|
業務類別
|
Biotechnology |
|
業務概覽
|
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies. |
| 公司地址
| 3928 Point Eden Way, Hayward, CA, USA, 94545 |
| 電話號碼
| +1 510 694-6200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.arcusbio.com |
| 員工數量
| 601 |
| Mr. Alexander Azoy |
Vice President, Finance and Principal Accounting Officer |
-- |
25/02/2026 |
| Ms. Jennifer Ann Jarrett |
Chief Operating Officer |
美元 625.00K |
22/04/2025 |
| Mr. Robert C. Goeltz, II |
Chief Financial Officer |
美元 510.00K |
25/02/2026 |
| Dr. Juan Carlos Jaen, PhD |
President |
美元 625.00K |
22/04/2025 |
| Dr. Richard Markus, M.D.,PhD |
Chief Medical Officer |
-- |
21/01/2025 |
| Dr. Terry Rosen, PhD |
Chairman of the Board and Chief Executive Officer |
美元 725.00K |
25/02/2026 |
| Ms. Carolyn C. Tang |
General Counsel |
-- |
22/04/2025 |
|
|
| Dr. Linda Higgins, PhD |
Director |
25/02/2026 |
| Dr. Dietmar Berger, M.D.,PhD |
Director |
25/02/2026 |
| Dr. Antoni Ribas, M.D.,PhD |
Independent Director |
25/02/2026 |
| Ms. Nicole Lambert |
Independent Director |
25/02/2026 |
| Dr. Yasunori Kaneko, M.D. |
Lead Independent Director |
25/02/2026 |
| Dr. David L. Lacey, M.D. |
Independent Director |
25/02/2026 |
| Dr. Terry Rosen, PhD |
Chairman of the Board and Chief Executive Officer |
25/02/2026 |
| Ms. Kathryn E. Falberg |
Independent Director |
25/02/2026 |
| Dr. Andrew J. Perlman,M.D.,PhD |
Independent Director |
25/02/2026 |
| Ms. Johanna Mercier |
Director |
25/02/2026 |
| Mr. Patrick C. Machado, J.D. |
Independent Director |
25/02/2026 |
|
|
|
|
